Trials / Completed
CompletedNCT01813474
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be investigated.
Detailed description
MTD - maximum tolerated dose
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | olaparib | tablet oral |
Timeline
- Start date
- 2013-03-25
- Primary completion
- 2016-08-31
- Completion
- 2016-08-31
- First posted
- 2013-03-19
- Last updated
- 2018-01-16
- Results posted
- 2017-12-12
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01813474. Inclusion in this directory is not an endorsement.